4D Molecular Therapeutics, Inc.
FDMT · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $85.2M | $40K | +212,925% |
| Operating income | −$160M | −$188M | +15.1% |
| Net income | −$140M | −$161M | +12.9% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $4.10M | $100K | +4,000% |
| Operating income | −$81.2M | −$61.2M | −32.7% |
| Net income | −$78.1M | −$56.9M | −37.3% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was 4D Molecular's revenue in FY2025?
- $85.2M in FY2025 (Fiscal year ended Dec 31, 2025), +212,925% vs $40K a year earlier, per its 10-K filed Mar 2026.
- Was 4D Molecular profitable in FY2025?
- No: net income was −$140M and operating income −$160M in FY2025.
- What was 4D Molecular's revenue in Q3 2026?
- $4.10M (+4,000% vs a year earlier), per its Form 10-Q filed Nov 12, 2026.